Navigation Links
Cynosure Appoints William T. Kelley as Senior Vice President of International Sales
Date:2/25/2009

Laser Industry Executive to Head Company's Network of International Subsidiaries and Distributors

WESTFORD, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the appointment of William T. Kelley as Senior Vice President of International Sales. He will be responsible for the company's direct subsidiaries in four European countries, Japan, China and Korea, and for Cynosure distributors covering an additional 55 countries.

"Bill brings more than 25 years of experience in the medical device industry and a track record of success in growing a global distribution organization," said Michael Davin, Cynosure's President and Chief Executive Officer. "Bill has extensive background in the aesthetic and surgical laser market, and is an ideal choice to help us expand the reach of our aesthetic products around the world."

Since 2004 Kelley was director of international sales at Sciton Inc., a privately held aesthetic device company based in Palo Alto, California, where he was responsible for all business activity outside the United States. Prior to that he served as vice president and general manager for Asclepion-Meditec Inc., the surgical laser division of international optics leader Carl Zeiss AG. As vice president of worldwide sales and marketing for Summit Technology, a maker of ophthalmic excimer laser systems, he supervised the company's direct sales forces in the United States, the United Kingdom and Scandinavia as well as distributors in other regions. From 1985 to 1991 he was general manager of Pfizer Laser Systems, the surgical laser division of Pfizer Corp.

"Cynosure has worked hard to build its base of di
'/>"/>

SOURCE Cynosure, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008
2. Cynosure to Announce Fourth-quarter and Full-year 2008 Financial Results on February 10
3. Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008
4. Cynosure Reports 21% Revenue Growth for the Third Quarter of 2008
5. Cynosure to Announce Second-Quarter 2008 Financial Results on July 29
6. Cynosure President and CEO Michael Davin Named Ernst & Young Entrepreneur of the Year(R) 2008 Award Winner in New England
7. Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
8. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
9. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
10. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
11. Cynosure Launches Three Aesthetic Products at American Academy of Dermatology 2008 Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...YHILL,N.J.,Nov.23/PRNewswire/--InasurveyofNewJerse...hiefFinancialOfficers,72percentdonotbelieveanewhea...tem. ,, Accordingtoresultsofthelatestsurveycond...untingfirm,theeconomytoppedthelistat85percentasthe...sestoits1500surveyssenttocompaniesfromallpartsofNe...
(Date:11/23/2009)...J. The Center for Science Writings at Stevens Ins...f God," a talk by Robert Wright, journalist and fo...09, 4:00-5:30 p.m. at the Babbio Center for Techno...pen to the public and the media., In his new boo...st Robert Wright, renowned for his popular works o...
(Date:11/23/2009)...Minn. -- Major medical errors self-reported by Ame...t and depression. Those findings appear today in t... Clinic-led study included collaborators from John..., In the confidential study, nearly 9 percent o...error in the three months prior to being surveyed....
(Date:11/23/2009)...N, Va. The Infectious Diseases Society of America...administration and the European Union to further t... 10 new antibiotics within the next 10 years, know...ganization (WHO) has identified antimicrobial resi...an health. , A new European Union report confirm...
(Date:11/23/2009)...in home-based settings get far more screen time t... , MONDAY, Nov. 23 (HealthDay News) --Young c...evision every day than previous reports have found... a new study finds. , Researchers from Seattle ...on surveyed day-care directors to find out how muc...
Breaking Medicine News(10 mins):Health News:Burnout and mental distress strongly related to errors by US surgeons 2Health News:10 x '20: ID experts call for 10 new antibiotics by 2020 2Health News:10 x '20: ID experts call for 10 new antibiotics by 2020 3Health News:Day Care Boosts Kids' TV Time 2Health News:Day Care Boosts Kids' TV Time 3
...iefu, vice minister of health in China has sought ... demand of organs by patients in their country//. ...ed for organ donations and the actual donations. ...onated by people after signing voluntary agreement...
...ng to a research conducted by Dr Michael Kisley, a...he US, older people have a more positive// outlook...e reported in the journal Psychological Science. ...ative aspects of life. The viewing was restricted ...
...nation of AZT, lamivudine, and nevirapine (AZT/3TC...e month after delivery resulted in significantly r...the HIV levels found in the breast milk of women w...s pilot study to examine the effect of using tripl...
...utes, perversions and public scandals – the stuff ...rs three centuries earlier,// according to new res...ing of erotic literature was already a social acti...tury Britain: "I tried to get a grip on just how m...
... has been declared free of neonatal tetanus by the... Kartar Devi said Saturday that a communication ha... welfare ministry, declaring that neonatal tetanus... a survey conducted by the central ministry on bir...
...s with arterial disease have relatively high rates...eart attack, stroke or //cardiovascular death) wit...f arterial locations afflicted, according to a stu...AD; narrowing of the arteries that supply the legs...
Other Medicine News:Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 3Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 4Health News:Sex – Three Hundred Years Ag 2Health News:Sex – Three Hundred Years Ag 3Health News:Atherothrombosis Associated With High Rates of Cardiovascular Events 2
(Date:11/23/2009)..., NEWYORK,Nov.23/PRNewswire/--Reportlinker.comanno...atalogue. ,, HolterMonitoringSystems-AGlobalMa...164324/Holter-Monitoring-Systems---A-Global-Market...pr&utm_campaign=prnewswire ,, Cardiovas...ents.High-riskpatientsneedtobecontinuouslymonitore...
(Date:11/23/2009)..., NEWYORK,Nov.23/PRNewswire/--Reportlinker.comanno...atalogue. ,, AnesthesiaDisposables-AWorldMarke...276/Anesthesia-Disposables---A-World-Market-Review...utm_campaign=prnewswire ,, Globalgeneralane...eeofsaturation.Despitetheconsiderablerisewitnessed...
(Date:11/23/2009)..., BIRMINGHAM,Ala.andNOIDA,India,Nov.23/PRNewswire-...amaatBirmingham(UAB),andSouthernResearchInstitutet...gtheircollectiveinnovationandenablingtechnologiesi...iseases.ItisauniqueU.S.-Indiaarbitragedandleverage...rdabletherapiesforpatientsworldwide.AMemorandumofU...
Breaking Medicine Technology:Reportlinker Adds Holter Monitoring Systems - A Global Market Review 2Reportlinker Adds Holter Monitoring Systems - A Global Market Review 3Reportlinker Adds Holter Monitoring Systems - A Global Market Review 4Reportlinker Adds Holter Monitoring Systems - A Global Market Review 5Reportlinker Adds Anesthesia Disposables - A World Market Review 2Reportlinker Adds Anesthesia Disposables - A World Market Review 3Reportlinker Adds Anesthesia Disposables - A World Market Review 4Reportlinker Adds Anesthesia Disposables - A World Market Review 5Reportlinker Adds Anesthesia Disposables - A World Market Review 6Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 2Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 3Jubilant Organosys, UAB and Southern Research Enter Into Drug Discovery Joint Venture 4OTCBB WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 61141 1OTCBB WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 61141 2OTCBB WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 61141 3Biotechnology Salutes Americas Veterans 3B Innovations Continue to Offer Improved Treatment and Care of Combat Troops 6171 1Biotechnology Salutes Americas Veterans 3B Innovations Continue to Offer Improved Treatment and Care of Combat Troops 6171 2WellTek MedX Group Completes Major Reorganization 6168 1WellTek MedX Group Completes Major Reorganization 6168 2
...e Francophone du Myelome (IFM),Trial Presented Dur...wire-FirstCall/ --,Millennium Pharmaceuticals, Inc...he comparative Phase III clinical trial evaluating...le myeloma (MM),patients. As induction therapy pri... based therapy produced a high complete remission,...
.../PRNewswire/ -- Portola,Pharmaceuticals, Inc. anno...linical data on its oral Factor Xa inhibitor and o... at the XXI Congress of,the International Society ...itzerland on July 6 through July 12, 2007. , The E...Company,s,lead compound PRT054021, is entitled "Ev...
Other Medicine Technology:Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 2Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 3Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 4Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 5Velcade (bortezomib) for Injection Based Induction Therapy,Delivered High Post-Transplant Complete Remission Rate, a Critical,Marker for Increased Overall Survival 6Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH) 2Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH) 3
GENIE BLOTTER
The Panther Semi-dry Electroblotter - Model HEP-3 (Complete System)
Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell
...inated DNA and RNA from agarose gels to hybridizat...s speed and efficiency of transfer by allowing hig...ated system allowing electrophoresis, gel treatmen...us 29 hours required for conventional methods ,Pos...
Medicine Products: